{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:44:27Z","timestamp":1792590267025,"version":"4.5.0"},"reference-count":38,"publisher":"American Chemical Society (ACS)","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100013415","name":"Purdue University Center for Cancer Research","doi-asserted-by":"publisher","award":["P30CA023168"],"award-info":[{"award-number":["P30CA023168"]}],"id":[{"id":"10.13039\/100013415","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-21-012-01-DMC"],"award-info":[{"award-number":["RSG-21-012-01-DMC"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014039","name":"DOD Prostate Cancer Research Program","doi-asserted-by":"publisher","award":["PC210004"],"award-info":[{"award-number":["PC210004"]}],"id":[{"id":"10.13039\/100014039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM125620"],"award-info":[{"award-number":["T32GM125620"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ross-Lynn fellowship from the BMCMP department at Purdue"},{"name":"Bilsland Fellowship from the Purdue College of Pharmacy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Proteolysis-targeting chimeras (PROTACs) have emerged as powerful chemical tools and therapeutics, yet their translation from preclinical models to humans remains inconsistent. Here, we systematically evaluate the activity of BRD9-targeting PROTACs in human and mouse systems to elucidate a key limitation in preclinical studies. Widely used CRBN- and VHL-recruiting degraders, including dBRD9 and VZ185, exhibit markedly reduced potency in mouse cells despite high sequence conservation of BRD9. Mechanistic interrogation reveals that species-specific differences in E3 ligases, particularly the Crbn I391 residue and structural variations in VHL, likely impair productive ternary complex formation. Expression of human CRBN or VHL, or introduction of the CrbnI391V mutation, increases degradation potency in mouse cells. Importantly, in vivo studies demonstrate enhanced BRD9 degradation in CrbnI391V mice using clinically relevant degraders. These findings highlight a critical barrier in PROTAC evaluation and establish humanized E3 ligase models as tools for more accurate assessment of on-target efficacy and toxicity.<\/jats:p>","DOI":"10.1021\/acschembio.6c00628","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:01:37Z","timestamp":1792587697000},"source":"Crossref","is-referenced-by-count":0,"title":["Improving PROTAC-Mediated Degradation in Mouse Models: BRD9 as a Case Study"],"prefix":"10.1021","author":[{"given":"Brayden P.","family":"Strohmier","sequence":"first","affiliation":[{"name":"Purdue University , , , ,","place":["West Lafayette, Indiana, United States, 47907"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5654-1859","authenticated-orcid":true,"given":"Jude T.","family":"Quarshie","sequence":"additional","affiliation":[{"name":"Purdue University , , , ,","place":["West Lafayette, Indiana, United States, 47907"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinky","family":"Raghuvanshi","sequence":"additional","affiliation":[{"name":"Purdue University , , , ,","place":["West Lafayette, Indiana, United States, 47907"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhmandeep","family":"Kaur","sequence":"additional","affiliation":[{"name":"Purdue University , , , ,","place":["West Lafayette, Indiana, United States, 47907"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella G","family":"Conjelko","sequence":"additional","affiliation":[{"name":"Purdue University , , , ,","place":["West Lafayette, Indiana, United States, 47907"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3072-1469","authenticated-orcid":true,"given":"Emily C.","family":"Dykhuizen","sequence":"additional","affiliation":[{"name":"Purdue University , , , ,","place":["West Lafayette, Indiana, United States, 47907"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"issue":"9","key":"2026102109013257600_cit1","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/nchembio.2115","article-title":"Sensitivity and Engineered Resistance of Myeloid Leukemia Cells to BRD9 Inhibition","volume":"12","author":"Hohmann","year":"2016","journal-title":"Nat. Chem. Biol."},{"issue":"21","key":"2026102109013257600_cit2","doi-asserted-by":"publisher","first-page":"5738","DOI":"10.1002\/anie.201611281","article-title":"Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands","volume":"56","author":"Remillard","year":"2017","journal-title":"Angew. Chem., Int. Ed."},{"issue":"11","key":"2026102109013257600_cit3","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1074\/jbc.ra117.001065","article-title":"Glioma Tumor Suppressor Candidate Region Gene 1 (GLTSCR1) and Its Paralog GLTSCR1-like Form SWI\/SNF Chromatin Remodeling Subcomplexes","volume":"293","author":"Alpsoy","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"1","key":"2026102109013257600_cit4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07528-9","article-title":"A Non-Canonical BRD9-Containing BAF Chromatin Remodeling Complex Regulates Naive Pluripotency in Mouse Embryonic Stem Cells","volume":"9","author":"Gatchalian","year":"2018","journal-title":"Nat. Commun."},{"issue":"12","key":"2026102109013257600_cit5","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41556-018-0221-1","article-title":"A Non-Canonical SWI\/SNF Complex Is a Synthetic Lethal Target in Cancers Driven by BAF Complex Perturbation","volume":"20","author":"Michel","year":"2018","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"2026102109013257600_cit6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09891-7","article-title":"BRD9 Defines a SWI\/SNF Sub-Complex and Constitutes a Specific Vulnerability in Malignant Rhabdoid Tumors","volume":"10","author":"Wang","year":"2019","journal-title":"Nat. Commun."},{"key":"2026102109013257600_cit7","doi-asserted-by":"publisher","DOI":"10.7554\/elife.41305","article-title":"Targeted Degradation of BRD9 Reverses Oncogenic Gene Expression in Synovial Sarcoma","volume":"7","author":"Brien","year":"2018","journal-title":"Elife"},{"issue":"9","key":"2026102109013257600_cit8","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1158\/1078-0432.ccr-22-3668","article-title":"BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma","volume":"29","author":"Kurata","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"2026102109013257600_cit9","doi-asserted-by":"publisher","DOI":"10.1111\/andr.70038","article-title":"BRD9 Inhibition as Potential Treatment Option for Testicular Germ Cell Tumors","author":"Hansen","year":"2025","journal-title":"Andrology"},{"issue":"11","key":"2026102109013257600_cit10","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04186-6","article-title":"BRD9 Inhibition Promotes PUMA-Dependent Apoptosis and Augments the Effect of Imatinib in Gastrointestinal Stromal Tumors","volume":"12","author":"Mu","year":"2021","journal-title":"Cell Death Dis."},{"issue":"4","key":"2026102109013257600_cit11","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1158\/0008-5472.can-20-1417","article-title":"BRD9 Is a Critical Regulator of Androgen Receptor Signaling and Prostate Cancer Progression","volume":"81","author":"Alpsoy","year":"2021","journal-title":"Cancer Res."},{"key":"2026102109013257600_cit12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2023.166983","article-title":"BRD9 Status Is a Major Contributor for Cysteine Metabolic Remodeling through MST and EAAT3 Modulation in Malignant Melanoma","volume":"1870","author":"Hip\u00f3lito","year":"2023","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"issue":"1","key":"2026102109013257600_cit13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.immuni.2020.06.011","article-title":"A Genome-Wide CRISPR Screen Reveals a Role for the Non-Canonical Nucleosome-Remodeling BAF Complex in Foxp3 Expression and Regulatory T Cell Function","volume":"53","author":"Loo","year":"2020","journal-title":"Immunity"},{"issue":"1","key":"2026102109013257600_cit14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2110812119","article-title":"BRD9 Regulates Interferon-Stimulated Genes during Macrophage Activation via Cooperation with BET Protein BRD4","volume":"119","author":"Ahmed","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"35","key":"2026102109013257600_cit15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2109517118","article-title":"Bromodomain Containing 9 (BRD9) Regulates Macrophage Inflammatory Responses by Potentiating Glucocorticoid Receptor Activity","volume":"118","author":"Wang","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"8","key":"2026102109013257600_cit16","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.immuni.2024.05.008","article-title":"Collaboration between Distinct SWI\/SNF Chromatin Remodeling Complexes Directs Enhancer Selection and Activation of Macrophage Inflammatory Genes","volume":"57","author":"Liao","year":"2024","journal-title":"Immunity"},{"key":"2026102109013257600_cit17","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202152823","article-title":"BRD9 Is a Druggable Component of Interferon-stimulated Gene Expression and Antiviral Activity","volume":"22","author":"B\u00f6rold","year":"2021","journal-title":"EMBO Rep."},{"key":"2026102109013257600_cit18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41418-024-01306-5","article-title":"BRD9 Regulates Normal Human Hematopoietic Stem Cell Function and Lineage Differentiation","author":"Garg","year":"2024","journal-title":"Cell Death Differ."},{"issue":"3","key":"2026102109013257600_cit19","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112010","article-title":"In-Depth Functional Analysis of BRD9 in Fetal Hematopoiesis Reveals Context-Dependent Roles","volume":"28","author":"Zhang","year":"2025","journal-title":"iScience"},{"issue":"7778","key":"2026102109013257600_cit20","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-019-1646-9","article-title":"Spliceosomal Disruption of the Non-Canonical BAF Complex in Cancer","volume":"574","author":"Inoue","year":"2019","journal-title":"Nature"},{"key":"2026102109013257600_cit21","doi-asserted-by":"publisher","first-page":"24848","DOI":"10.1021\/acs.jmedchem.5c01317","article-title":"Discovery of CFT8634, a Potent, Selective, and Orally Bioavailable Heterobifunctional Degrader of BRD9","volume":"68","author":"Jackson","year":"2025","journal-title":"J. Med. Chem."},{"issue":"4","key":"2026102109013257600_cit22","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1158\/1078-0432.ccr-24-2583","article-title":"A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors","volume":"31","author":"Livingston","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"24","key":"2026102109013257600_cit23","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1111\/bph.17332","article-title":"Translational Modelling to Predict Human Pharmacokinetics and Pharmacodynamics of a Bruton\u2019s Tyrosine Kinase-targeted Protein Degrader BGB-16673","volume":"181","author":"Wu","year":"2024","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"2026102109013257600_cit24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s42003-020-0868-6","article-title":"Extended Pharmacodynamic Responses Observed upon PROTAC-Mediated Degradation of RIPK2","volume":"3","author":"Mares","year":"2020","journal-title":"Commun. Biol."},{"issue":"1","key":"2026102109013257600_cit25","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","article-title":"Targeted Protein Degradation: Advances in Drug Discovery and Clinical Practice","volume":"9","author":"Zhong","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"16","key":"2026102109013257600_cit26","doi-asserted-by":"publisher","first-page":"6187","DOI":"10.1074\/jbc.m117.816868","article-title":"Ligand-Mediated Protein Degradation Reveals Functional Conservation among Sequence Variants of the CUL4-Type E3 Ligase Substrate Receptor Cereblon","volume":"293","author":"Akuffo","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"14","key":"2026102109013257600_cit27","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1182\/blood-2018-05-852798","article-title":"Crbn I391V Is Sufficient to Confer in Vivo Sensitivity to Thalidomide and Its Derivatives in Mice","volume":"132","author":"Fink","year":"2018","journal-title":"Blood"},{"issue":"46","key":"2026102109013257600_cit28","doi-asserted-by":"publisher","first-page":"11802","DOI":"10.1073\/pnas.1814446115","article-title":"Humanized Cereblon Mice Revealed Two Distinct Therapeutic Pathways of Immunomodulatory Drugs","volume":"115","author":"Gemechu","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"19","key":"2026102109013257600_cit29","doi-asserted-by":"publisher","first-page":"8216","DOI":"10.1039\/d2cs00387b","article-title":"Discovery of Small Molecule Ligands for the von Hippel-Lindau (VHL) E3 Ligase and Their Use as Inhibitors and PROTAC Degraders","volume":"51","author":"Diehl","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"2","key":"2026102109013257600_cit30","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1021\/acs.jmedchem.8b01413","article-title":"Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel\u2013Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7","volume":"62","author":"Zoppi","year":"2019","journal-title":"J. Med. Chem."},{"issue":"2","key":"2026102109013257600_cit31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1021\/acs.jmedchem.7b00675","article-title":"Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel\u2013Lindau (VHL) E3 Ubiquitin Ligase: Structure\u2013Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-Dimethylbutanoyl)-4-hydroxy-N-(4-(4-Methylthiazol-5-Yl)Benzyl)Pyrrolidine-2-Carboxamide (VH298)","volume":"61","author":"Soares","year":"2018","journal-title":"J. Med. Chem."},{"issue":"18","key":"2026102109013257600_cit32","doi-asserted-by":"publisher","first-page":"12776","DOI":"10.1021\/acs.jmedchem.3c00434","article-title":"Expanding the Structural Diversity at the Phenylene Core of Ligands for the von Hippel\u2013Lindau E3 Ubiquitin Ligase: Development of Highly Potent Hypoxia-Inducible Factor-1\u03b1 Stabilizers","volume":"66","author":"Vu","year":"2023","journal-title":"J. Med. Chem."},{"issue":"21","key":"2026102109013257600_cit33","doi-asserted-by":"publisher","first-page":"22246","DOI":"10.1021\/acs.jmedchem.5c00773","article-title":"Design, Optimization, and Development of RIPK1 Degraders with Improved Pharmacokinetic and Pharmacodynamic Properties","volume":"68","author":"Lu","year":"2025","journal-title":"J. Med. Chem."},{"issue":"13","key":"2026102109013257600_cit34","doi-asserted-by":"publisher","first-page":"11326","DOI":"10.1021\/acs.jmedchem.4c00883","article-title":"Discovery of a Highly Potent and Selective BRD9 PROTAC Degrader Based on E3 Binder Investigation for the Treatment of Hematological Tumors","volume":"67","author":"Duan","year":"2024","journal-title":"J. Med. Chem."},{"key":"2026102109013257600_cit35","doi-asserted-by":"publisher","first-page":"6634","DOI":"10.1021\/acs.jmedchem.5c02858","article-title":"Discovery of XYD270 as a Potent, Selective, and Orally Efficacious BRD9 PROTAC for Cancer Therapy","volume":"69","author":"Huang","year":"2026","journal-title":"J. Med. Chem."},{"key":"2026102109013257600_cit36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115872","article-title":"Structure-Based Identification of New Orally Bioavailable BRD9-PROTACs for Treating Acute Myelocytic Leukemia","volume":"262","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"2026102109013257600_cit37","doi-asserted-by":"publisher","first-page":"35481","DOI":"10.1021\/jacs.5c09857","article-title":"Discovery of BRD9 Molecular Glue Degraders That Spare Cardiomyocytes","volume":"147","author":"Byun","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"2026102109013257600_cit38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/bs.mie.2022.10.005","article-title":"Crystallization of VHL-Based PROTAC-Induced Ternary Complexes","volume":"681","author":"Wijaya","year":"2023","journal-title":"Methods Enzymol."}],"container-title":["ACS Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acschembio.6c00628","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/acbcct\/article-pdf\/doi\/10.1021\/acschembio.6c00628\/68927428\/cb-2026-00628v.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/acbcct\/article-pdf\/doi\/10.1021\/acschembio.6c00628\/68927428\/cb-2026-00628v.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:10:43Z","timestamp":1792588243000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/acbcct\/article\/doi\/10.1021\/acschembio.6c00628\/5455195\/Improving-PROTAC-Mediated-Degradation-in-Mouse"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":38,"URL":"https:\/\/doi.org\/10.1021\/acschembio.6c00628","relation":{},"ISSN":["1554-8929","1554-8937"],"issn-type":[{"value":"1554-8929","type":"print"},{"value":"1554-8937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]}}}